Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the West, and about 30% of all reported leukemias is CLL. This disease occurs when the patient’s bone marrow produces too many abnormal white blood cells (WBC), or lymphocytes, which never become normal, infection fighting WBC. As the amount of these unhealthy lymphocytes increasing, they interfere with the normal production process of other important blood cells. More than 50% of CLL patients are older than 70, and individuals younger than 40 are rarely diagnosed with this disease. Researchers are not certain what are the exact reasons that start CLL, however, exposure to chemicals (e.g. Agent Orange druing the Vietnam War), family history of CLL, getting treated with immunosuppressive agent are possible to increase the risk of developing CLL.
Signs, symptoms and treatments
CLL always accompanies multiple complicated symptoms, including infection, abnormal bleeding, shortness of breath, chill and swollen lymph nodes. The conventional treatments of CLL focus on disease control that achieves a chronic indolent status. During the past ten years, aggressive research in the understanding of CLL has generated innovative therapeutic approaches based on molecular biology.
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE